Sign Out
Moderate to severe vasomotor symptoms associated with menopause
Adult: Initially, 0.3 mg per day, cyclically (either 3 weeks on and 1 week off or 25 days on and 5 days off) or daily, depending on patient’s condition. Subsequent dosage adjustment may be made based on patient response. Use lowest effective dose for the shortest duration.
Oral
Vaginal atrophy associated with menopause, Vulvar atrophy associated with menopause
Adult: Initially, 0.3 mg per day, cyclically (either 3 weeks on and 1 week off or 25 days on and 5 days off) or daily, depending on patient’s condition. Subsequent dosage adjustment may be made based on patient response. Use lowest effective dose for the shortest duration.
Oral
Hypogonadism-associated estrogen deficiency
Adult: 0.3 or 0.625 mg per day given cyclically (either 3 weeks on and 1 week off or 25 days on and 5 days off). Dose may be titrated in 6-12-month intervals; add progestin treatment to maintain bone mineral density once skeletal maturity is achieved.
Oral
Castration-associated estrogen deficiency, Primary ovarian failure-associated estrogen deficiency
Adult: 1.25 mg per day given cyclically (either 3 weeks on and 1 week off or 25 days on and 5 days off). Dose may be adjusted based on patient response. Use lowest effective dose for the shortest duration.
Oral
Prophylaxis of osteoporosis in postmenopausal women
Adult: Initially, 0.3 mg per day, cyclically (either 3 weeks on and 1 week off or 25 days on and 5 days off) or daily, depending on patient's condition. Subsequent dosage adjustment may be made based on patient response. Use lowest effective dose for the shortest duration.
Parenteral
Abnormal uterine bleeding
Adult: 25 mg via slow IV or IM inj, may repeat dose after 6-12 hours, if needed.
Vaginal
Kraurosis vulvae associated with menopause, Menopausal atrophic vaginitis
Adult: As 0.0625% cream: Initially, 0.5 g per day, given cyclically for 3 weeks of a 4-week cycle (21 days on, 7 days off). Adjust dose according to response (range: 0.5-2 g per day) Lowest effective dose should be used. Discontinue as promptly as possible.
Vaginal
Moderate dyspareunia associated with menopause, Severe dyspareunia associated with menopause
Adult: 0.5 g twice weekly as a continuous regimen (e.g. Monday and Thursday) or once daily cyclically (21 days on, 7 days off).
